Back
Corporate News
Fredun Pharmaceuticals reports Rs 228.25 crore income, a 90.44% increase year-over-year
06-Aug-2026, 02:45
Fredun Pharmaceuticals Limited (BSE: FREDUN | 539730) announced its unaudited financial results for the first quarter of fiscal year 2027, reporting total income of Rs 228.25 crore, a 90.44% year-over-year increase, while EBITDA surged by 92.90% to Rs 32.78 crore and net profit rose 94.63% to Rs 13.17 crore. The company, which offers a portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products, also recently allotted 1.10 crore bonus equity shares in a 2:1 ratio to eligible shareholders, increasing its issued and paid-up equity share capital from 55.13 lakh shares to 1.65 crore shares.
Fredun Pharmaceuticals Limited (BSE: FREDUN | 539730) announced its unaudited financial results for the first quarter of fiscal year 2027, reporting total income of Rs 228.25 crore, a 90.44% year-over-year increase, while EBITDA surged by 92.90% to Rs 32.78 crore and net profit rose 94.63% to Rs 13.17 crore. The company, which offers a portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products, also recently allotted 1.10 crore bonus equity shares in a 2:1 ratio to eligible shareholders, increasing its issued and paid-up equity share capital from 55.13 lakh shares to 1.65 crore shares.